more

REGENXBIO (RGNX)

(Delayed Data from NSDQ)

$16.19 USD

+0.13 (0.81%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $16.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is a Beat in the Cards for Bristol-Myers' (BMY) Q3 Earnings?

by Zacks Equity Research Published on October 30,2020

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports third-quarter 2020 results.

What's in the Cards for Regeneron's (REGN) Q3 Earnings?

by Zacks Equity Research Published on October 30,2020

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.

Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?

by Zacks Equity Research Published on October 29,2020

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2020 results.

What's in the Cards for Cassava (SAVA) This Earnings Season?

by Zacks Equity Research Published on October 26,2020

Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.

Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on August 06,2020

Regenxbio (RGNX) delivered earnings and revenue surprises of -2.25% and -14.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

RGNXPositive Net Change

Analysts Estimate Regenxbio (RGNX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on July 29,2020

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RGNXPositive Net Change

Regenxbio (RGNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research Published on April 28,2020

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RGNXPositive Net Change

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on February 26,2020

Regenxbio (RGNX) delivered earnings and revenue surprises of -80.00% and -70.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

RGNXPositive Net Change

Applied Genetic Stock Up on Favorable Eye Therapy Study Data

by Zacks Equity Research Published on January 10,2020

Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.

biotechs

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 05,2019

Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

RGNXPositive Net Change

Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA

by Zacks Equity Research Published on October 15,2019

Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.

biotechs

Wet AMD Space in Focus: New Drug Approvals & Key Advancements

by Ekta Bagri Published on October 10,2019

The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

Ultragenyx Gets FDA Approval for Label Expansion of Crysvita

by Zacks Equity Research Published on October 02,2019

Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.

biotechs

REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%

by Zacks Equity Research Published on September 13,2019

REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

medical

Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA

by Zacks Equity Research Published on September 04,2019

The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.

biotechs

Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues

by Zacks Equity Research Published on August 23,2019

Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.

biotechs

Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on August 07,2019

Regenxbio (RGNX) delivered earnings and revenue surprises of -44.00% and -65.15%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

RGNXPositive Net Change

Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?

by Zacks Equity Research Published on July 02,2019

Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.

RGNXPositive Net Change

medical

REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%

by Zacks Equity Research Published on May 28,2019

REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

RGNXPositive Net Change

medical

4 Gene Therapy Players Likely to Become Buyout Targets in 2019

by Indrajit Bandyopadhyay Published on April 08,2019

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.